| Market Capitalization (Millions $) |
767 |
| Shares
Outstanding (Millions) |
90 |
| Employees |
201 |
| Revenues (TTM) (Millions $) |
0 |
| Net Income (TTM) (Millions $) |
-88 |
| Cash Flow (TTM) (Millions $) |
3 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Chimerix Inc is an American biopharmaceutical company that focuses on developing medicines for various viral infections and cancer treatment. The company has been operational since 2002 and is headquartered in Durham, North Carolina.
Chimerix's primary focus is on the development of antiviral therapies for life-threatening viral infections. One of its most notable products is brincidofovir, an antiviral drug that is used to treat cytomegalovirus (CMV). CMV is a viral infection that is prevalent in people with weakened immune systems, such as organ transplant recipients and HIV/AIDS patients.
In addition to CMV, Chimerix is also working on developing therapies for other viral infections such as adenovirus, BK virus, and human papillomavirus (HPV). The company's research in this area involves the use of small molecules to target viral proteins.
Apart from antiviral therapies, Chimerix is also involved in the development of oncology drugs. The company's lead oncology candidate is dociparstat sodium, a drug that targets the heparanase enzyme, which plays a critical role in the development and spread of cancer cells. Dociparstat sodium is being investigated for its potential use in the treatment of acute myeloid leukemia (AML) and multiple myeloma.
The company has also developed a proprietary lipid nanoparticle delivery technology platform, which is being used to enhance the delivery of RNA-based drugs, including gene therapy and gene editing.
As of 2021, Chimerix has a research and development team of over 60 scientists and researchers working in their state-of-the-art facility in Durham. The company's innovative approach to drug development has earned it numerous accolades, including the Frost & Sullivan 2018 Best Practices Award for New Product Innovation.
Company Address: 2505 Meridian Parkway Durham 27713 NC
Company Phone Number: 806-1074 Stock Exchange / Ticker: NASDAQ CMRX
|
0.13%